Apealea

paclitaxel

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).

Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment.

Apealea contains the active substance paclitaxel.

: Apealea is available as a powder to make up a solution for infusion (drip) into a vein. The paclitaxel in Apealea is formulated in tiny particles, called micelles, to help it dissolve in the infusion solvent. It should not be interchanged with other medicines containing paclitaxel.
The medicine can only be obtained with a prescription and should be given under the supervision of a specialist in the treatment of cancer.
The dose of Apealea is 250 mg per square metre (calculated based on height and body weight) and is given by infusion over about 1 hour, once every 3 weeks, for 6 cycles of treatment. Doses may be delayed or reduced by the doctor, or treatment may be stopped, if severe side effects occur; doses should also be reduced in patients with moderate or severe reduction in liver function. Patients are also treated with a platinum-based medicine, carboplatin.
For more information about using Apealea, see the package leaflet or contact your doctor or pharmacist.

: The active substance in Apealea, paclitaxel, is a cancer medicine that has been used in the EU for many years. It belongs to the group of cancer medicines known as the ‘taxanes’. Paclitaxel blocks a stage of cell division in which the cell’s internal ‘skeleton’ is dismantled to allow the cell to divide. By keeping this structure intact the cells cannot divide and they eventually die.

: Apealea has been shown to be as effective as a conventional formulation of paclitaxel in one main study involving further treatment of 789 women whose ovarian, fallopian tube or peritoneal cancer had come back. Patients also received a platinum-based cancer medicine, carboplatin. The average length of time that patients lived without their disease coming back yet again was 10.3 months with Apealea, and 10.1 months with conventional paclitaxel.
Supportive data from the study showed that the average time that patients lived after treatment was 25.7 months among those given Apealea and 24.8 months for those given conventional paclitaxel.

: The most common side effects with Apealea (which may affect more than 1 in 10 people) are neutropenia (low numbers of white blood cells called neutrophils), stomach and gut disorders such as diarrhoea, nausea (feeling sick) and vomiting, peripheral neuropathy (nerve damage in hands and feet), joint and muscle pain, and reactions such as redness, soreness and inflammation of the veins at the site of infusion. For the full list of side effects of Apealea, see the package leaflet.
Apealea must not be used in patients who are breast feeding or those who already have low levels of neutrophils in the blood. For the full list of restrictions, see the package leaflet.

: The European Medicines Agency considered that Apealea was as effective as conventional paclitaxel, and could be a valuable alternative in combination with carboplatin. While the new formulation might be associated with more infusion site reactions, and studies suggested stronger effects on blood cells and the gut, these were considered manageable and the overall benefits and risks are consistent with those of other paclitaxel medicines. The Agency therefore decided that Apealea’s benefits are greater than its risks and it can be authorised for use in the EU.

: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Apealea have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Apealea are continuously monitored. Side effects reported with Apealea are carefully evaluated and any necessary action taken to protect patients.

: Apealea received a marketing authorisation valid throughout the EU on 20 November 2018.

List item

Apealea : EPAR - Medicine overview (PDF/104.9 KB)

First published: 05/12/2018
EMA/791927/2018
- Bulgarian
  (PDF/119.32 KB)
- Croatian
  (PDF/117.54 KB)
- Czech
  (PDF/117.36 KB)
- Danish
  (PDF/97.76 KB)
- Dutch
  (PDF/97.96 KB)
- Estonian
  (PDF/88.31 KB)
- Finnish
  (PDF/96.07 KB)
- French
  (PDF/100.35 KB)
- German
  (PDF/102.41 KB)
- Greek
  (PDF/118.51 KB)
- Hungarian
  (PDF/117.74 KB)
- Italian
  (PDF/98.21 KB)
- Latvian
  (PDF/122.68 KB)
- Lithuanian
  (PDF/117.36 KB)
- Maltese
  (PDF/120.74 KB)
- Polish
  (PDF/120.24 KB)
- Portuguese
  (PDF/99.96 KB)
- Romanian
  (PDF/117.13 KB)
- Slovak
  (PDF/118.91 KB)
- Slovenian
  (PDF/116.36 KB)
- Spanish
  (PDF/99.64 KB)
- Swedish
  (PDF/97.71 KB)
List item

Apealea : EPAR - Risk-management-plan summary (PDF/206.08 KB)

First published: 05/12/2018

This EPAR was last updated on 12/09/2022

Authorisation details

Product details
Name	Apealea
Agency product number	EMEA/H/C/004154
Active substance	paclitaxel
International non-proprietary name (INN) or common name	paclitaxel
Therapeutic area (MeSH)	Ovarian Neoplasms
Anatomical therapeutic chemical (ATC) code	L01CD01

Publication details
Marketing-authorisation holder	Inceptua AB
Revision	6
Date of issue of marketing authorisation valid throughout the European Union	20/11/2018
Contact address	Gustavslundsv. 143 16751 Bromma Sweden

Product information

09/09/2022 Apealea - EMEA/H/C/004154 - IB/0015

List item

Apealea : EPAR - Product information (PDF/371.56 KB)

First published: 05/12/2018
Last updated: 12/09/2022
- Bulgarian
  (PDF/574.75 KB)
- Croatian
  (PDF/531.44 KB)
- Czech
  (PDF/555.29 KB)
- Danish
  (PDF/520.42 KB)
- Dutch
  (PDF/375.32 KB)
- Estonian
  (PDF/363.61 KB)
- Finnish
  (PDF/382.02 KB)
- French
  (PDF/408.56 KB)
- German
  (PDF/384.84 KB)
- Greek
  (PDF/626.96 KB)
- Hungarian
  (PDF/489.77 KB)
- Icelandic
  (PDF/361.44 KB)
- Italian
  (PDF/376.09 KB)
- Latvian
  (PDF/558.67 KB)
- Lithuanian
  (PDF/561.33 KB)
- Maltese
  (PDF/725.78 KB)
- Norwegian
  (PDF/367.52 KB)
- Polish
  (PDF/527.86 KB)
- Portuguese
  (PDF/370.42 KB)
- Romanian
  (PDF/561.69 KB)
- Slovak
  (PDF/517.06 KB)
- Slovenian
  (PDF/509.24 KB)
- Spanish
  (PDF/370.91 KB)
- Swedish
  (PDF/364.14 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Apealea : EPAR - All authorised presentations (PDF/11.63 KB)

First published: 05/12/2018
- Bulgarian
  (PDF/32.83 KB)
- Croatian
  (PDF/25.31 KB)
- Czech
  (PDF/26.5 KB)
- Danish
  (PDF/11.39 KB)
- Dutch
  (PDF/11.47 KB)
- Estonian
  (PDF/11.38 KB)
- Finnish
  (PDF/11.34 KB)
- French
  (PDF/11.46 KB)
- German
  (PDF/11.58 KB)
- Greek
  (PDF/29.96 KB)
- Hungarian
  (PDF/17.75 KB)
- Icelandic
  (PDF/10.8 KB)
- Italian
  (PDF/11.48 KB)
- Latvian
  (PDF/28.85 KB)
- Lithuanian
  (PDF/25.74 KB)
- Maltese
  (PDF/29.93 KB)
- Norwegian
  (PDF/10.84 KB)
- Polish
  (PDF/29.06 KB)
- Portuguese
  (PDF/11.53 KB)
- Romanian
  (PDF/28.18 KB)
- Slovak
  (PDF/26.17 KB)
- Slovenian
  (PDF/17.89 KB)
- Spanish
  (PDF/11.56 KB)
- Swedish
  (PDF/17.64 KB)

Pharmacotherapeutic group

Antineoplastic agents
Taxanes

Therapeutic indication

Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

Assessment history

Changes since initial authorisation of medicine

List item

Apealea : EPAR - Procedural steps taken and scientific information after the authorisation (PDF/164.88 KB)

First published: 10/05/2019
Last updated: 12/09/2022
List item

Apealea-H-C-PSUSA-00002264-201812 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (PDF/102.66 KB)

First published: 27/11/2019
EMA/637582/2019
List item

Apealea : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - Annex I (PDF/161.6 KB)

First published: 27/11/2019
- Bulgarian
  (PDF/214.17 KB)
- Croatian
  (PDF/253.35 KB)
- Czech
  (PDF/240.7 KB)
- Danish
  (PDF/98.17 KB)
- Dutch
  (PDF/109.36 KB)
- Estonian
  (PDF/141.66 KB)
- Finnish
  (PDF/97.5 KB)
- French
  (PDF/99.94 KB)
- German
  (PDF/100.68 KB)
- Greek
  (PDF/216.9 KB)
- Hungarian
  (PDF/203.14 KB)
- Icelandic
  (PDF/97.6 KB)
- Italian
  (PDF/101.51 KB)
- Latvian
  (PDF/239.15 KB)
- Lithuanian
  (PDF/270.31 KB)
- Maltese
  (PDF/231.61 KB)
- Norwegian
  (PDF/107.7 KB)
- Polish
  (PDF/233.05 KB)
- Portuguese
  (PDF/109.3 KB)
- Romanian
  (PDF/226.05 KB)
- Slovak
  (PDF/247.65 KB)
- Slovenian
  (PDF/241.9 KB)
- Spanish
  (PDF/100.01 KB)
- Swedish
  (PDF/107.92 KB)

Apealea

Table of contents

Overview

Apealea : EPAR - Medicine overview (PDF/104.9 KB)

Apealea : EPAR - Risk-management-plan summary (PDF/206.08 KB)

Authorisation details

Product information

Apealea : EPAR - Product information (PDF/371.56 KB)

Apealea : EPAR - All authorised presentations (PDF/11.63 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Apealea : EPAR - Procedural steps taken and scientific information after the authorisation (PDF/164.88 KB)

Apealea-H-C-PSUSA-00002264-201812 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (PDF/102.66 KB)

Apealea : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - Annex I (PDF/161.6 KB)

Initial marketing-authorisation documents

Apealea : Orphan designation withdrawal assessment report (initial authorisation) (PDF/168.04 KB)

Apealea : EPAR - Public assessment report (PDF/6.53 MB)

CHMP summary of positive opinion for Apealea (PDF/67.42 KB)

News

More information on Apealea

How useful was this page?